Brokerages Set Neogen Corporation (NASDAQ:NEOG) Price Target at $10.67

Neogen Corporation (NASDAQ:NEOG) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $10.6667.

Several equities research analysts recently commented on the company. Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 24th.

Neogen News Roundup

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Neogen reported fiscal Q4 adjusted earnings of $0.09 per share, above the $0.05 analyst consensus and substantially better than the $2.82-per-share loss reported in the year-ago quarter. Revenue of $225.3 million also exceeded estimates of $212.35 million. Neogen Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Management forecast fiscal 2027 revenue of $880 million to $885 million, above the $851.1 million consensus estimate. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. Neogen Fiscal 2027 Guidance
• Positive Sentiment: The company expects fiscal 2027 adjusted EBITDA of approximately $180 million to $182 million, signaling anticipated improvement in profitability and supporting the favorable investor reaction. Neogen Fiscal 2026 Results
• Neutral Sentiment: Despite the earnings beat, quarterly revenue was essentially flat year over year, down 0.1%, indicating that the stronger outlook depends on future growth rather than current top-line acceleration.
• Neutral Sentiment: Analysts’ average price target is approximately $10.67, below the stock’s recent trading level, suggesting valuation and expectations may limit additional upside. Analysts Set Neogen Price Target
• Negative Sentiment: Neogen plans to increase research and development spending by roughly 50% in fiscal 2027. Although intended to support longer-term growth, the investment could pressure near-term margins and earnings.

Neogen Stock Up 4.4%

Neogen stock opened at $12.04 on Friday. Neogen has a 52 week low of $4.56 and a 52 week high of $12.15. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -401.33, a PEG ratio of 5.39 and a beta of 1.80. The company’s 50-day moving average price is $9.44 and its two-hundred day moving average price is $9.62. The company has a current ratio of 3.82, a quick ratio of 2.84 and a debt-to-equity ratio of 0.38.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. The company had revenue of $225.30 million during the quarter, compared to analyst estimates of $212.35 million. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The business’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.82) EPS. On average, analysts expect that Neogen will post 0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. UMB Bank n.a. lifted its holdings in Neogen by 238.2% in the 4th quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after acquiring an additional 4,523 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Neogen by 816.9% in the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after purchasing an additional 6,764 shares in the last quarter. Cresset Asset Management LLC bought a new stake in shares of Neogen in the 2nd quarter worth approximately $53,000. Evergreen Capital Management LLC acquired a new stake in Neogen during the second quarter valued at approximately $56,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Neogen by 3,158.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock valued at $58,000 after purchasing an additional 8,054 shares during the last quarter. Institutional investors own 96.73% of the company’s stock.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.